In vitro evaluation of cytochrome P450-mediated drug interactions between cytarabine, idarubicin, itraconazole and caspofungin

Hematology

Volumn 9, Issue 3, 2004, Pages 217-221

  Colburn, Dawn E ^a   Giles, Francis J ^a   Oladovich, Debra ^b   Smith, Judith A ^b  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Caspofungin; CYP450; Cytarabine; Idarubicin; Itaconazole; Metabolism

Indexed keywords

BENZYL DERIVATIVE; CASPOFUNGIN; COUMARIN DERIVATIVE; CYTARABINE; CYTOCHROME P450 1A2; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; CYTOCHROME P450 INHIBITOR; CYTOCHROME P450 ISOENZYME; FURAFYLLINE; IDARUBICIN; ITRACONAZOLE; KETOCONAZOLE; QUERCETIN; QUINIDINE; SULFAPHENAZOLE;

ARTICLE; CONTROLLED STUDY; DRUG DETERMINATION; DRUG METABOLISM; ENZYME METABOLISM; ENZYME SUBSTRATE COMPLEX; HIGH THROUGHPUT SCREENING; IN VITRO STUDY; METABOLIC INHIBITION; PRIORITY JOURNAL;

EID: 3242876326     PISSN: 10245332     EISSN: None     Source Type: Journal    
DOI: 10.1080/10245330410001701585     Document Type: Article

References (17)

1. Jemal, A., Murray, T., Samuels, A., Ghafoor, A., Ward, E. and Thun, M.J. (2003) "Cancer statistics", CA Cancer J. Clin. 53, 5.
2. Giles, F.J., Keating, A., Goldstone, A.H., Avivi, I., Willman, C.L. and Kantarjian, H.M. (2002) "Acute myeloid leukemia", Hematology, 73, (Am. Soc. Hematol. Educ. Program).
3. Carella, A.M., Berman, E., Maraone, M.P. and Ganzina, F. (1990) "Idarubicin in the treatment of acute leukemias. An overview of preclinical and clinical studies", Haematologica 75, 159.
4. Giles, F.J. (1998) "Monocyte-macrophages, granulocyte-macrophage colony-stimulating factor, and prolonged survival among patients with acute myeloid leukemia and stem cell transplants", Clin. Infect. Dis. 26, 1282.
5. Slavin, M.A., Osborne, B., Adams, R., et al. (1995) "Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation - a prospective, randomized, double-blind study", J. Infect. Dis. 171, 1545.
6. Marr, K.A., Seidel, K., Slavin, M.A., et al. (2000) "Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial", Blood 96, 2055.
7. Winston, D.J., Chandrasekar, P.H., Lazarus, H.M., et al. (1993) "Fluconazole prophylaxis of fungal infections in patients with acute leukemia. Results of a randomized placebo-controlled, double-blind, multicenter trial", Ann. Intern. Med. 118, 495.
8. Menichetti, F., Del Favero, A., Martino, P., et al. (1999) "Itraconazole oral solution as prophylaxis for fungal infections in neutropenic patients with hematologic malignancies: a randomized, placebo-controlled, double-blind, multicenter trial. GIMEMA Infection Program. Gruppo Italiano Malattie Ematologiche dell' Adulto", Clin. Infect. Dis. 28, 250.
9. Morgenstern, G.R., Prentice, A.G., Prentice, H.G., Ropner J.E., Schey, S.A. and Warnock, D.W. (1999) "A randomized controlled trial of itraconazole versus fluconazole for the prevention of fungal infections in patients with haematological malignancies. U.K. Multicentre Antifungal Prophylaxis Study Group", Br. J. Haematol. 105, 901.
10. Nucci, M., Biasoli, I., Akiti, T., et al. (2000) "A double-blind, randomized, placebo-controlled trial of itraconazole capsules as antifungal prophylaxis for neutropenic patients", Clin. Infect. Dis. 30, 300.
11. Venkatakrishnan, K., von Moltke, L.L. and Greenblatt, D.J. (2000) "Effects of the antifungal agents on oxidative drug metabolism: clinical relevance", Clin. Pharmacokinet. 38, 111.
12. Zuckerman, J.M. and Tunkel, A.R. (1994) "Itraconazole: a new triazole antifungal agent", Infect. Control Hosp. Epidemiol. 15, 397.
13. Crespi, C.L., Miller, V.P. and Penman, B.W. (1997) "Microtiter plate assays for inhibition of human, drug-metabolizing cytochromes P450", Anal. Biochem. 248, 188.
14. Stone, E.A., Fung, H.B. and Kirschenbaum, H.L. (2002) "Caspofungin: an echinocandin antifungal agent", Clin. Ther. 24, 351.
15. Dresser, G.K., Spence, J.D. and Bailey, D.G. (2000) "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition", Clin. Pharmacokinet. 38, 41.
16. Buggia, I., Zecca, M., Alessandrino, E.P., et al. (1996) "Itraconazole can increase systemic exposure to busulfan in patients given bone marrow transplantation. GITMO (Gruppo Italiano Trapianto di Midollo Osseo)", Anticancer Res. 16, 2083.
17. Gillies, J., Hung, K.A., Fitzsimons, E. and Soutar, R. (1998) "Severe vincristine toxicity in combination with itraconazole" , Clin. Lab. Haematol. 20, 123.